Cargando…
Showing Value in Newborn Screening: Challenges in Quantifying the Effectiveness and Cost-Effectiveness of Early Detection of Phenylketonuria and Cystic Fibrosis
Decision makers sometimes request information on the cost savings, cost-effectiveness, or cost-benefit of public health programs. In practice, quantifying the health and economic benefits of population-level screening programs such as newborn screening (NBS) is challenging. It requires that one spec...
Autor principal: | Grosse, Scott D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4686149/ https://www.ncbi.nlm.nih.gov/pubmed/26702401 http://dx.doi.org/10.3390/healthcare3041133 |
Ejemplares similares
-
Newborn Screening and Treatment of Phenylketonuria: Projected Health Outcomes and Cost-Effectiveness
por: Chen, Huey-Fen, et al.
Publicado: (2021) -
Coexistence of cystic fibrosis and phenylketonuria.
por: Greeves, L. G., et al.
Publicado: (1997) -
Diagnostic and Communication Challenges in Cystic Fibrosis Newborn Screening
por: DeCelie-Germana, Joan Kathleen, et al.
Publicado: (2023) -
Challenges in Assessing the Cost-Effectiveness of Newborn Screening: The Example of Congenital Adrenal Hyperplasia
por: Grosse, Scott D., et al.
Publicado: (2020) -
Newborn Screening for Cystic Fibrosis in Delaware
por: Shenoy, Ambika, et al.
Publicado: (2018)